Moonlake Immunotherapeutics 10-Q quarterly reports

MoonLake Immunotherapeutics' Q2 2026 Form 10-Q details positive clinical trial updates for Sonelokimab (SLK) and a strong cash position, while acknowledging continued operating losses.

MoonLake Immunotherapeutics reports increased R&D spending and net loss in Q1 2026, driven by clinical trial progression and stock option expense, while maintaining sufficient capital through 2027.

MoonLake Immunotherapeutics reported increased losses and mixed Phase 3 hidradenitis suppurativa trial results, impacting its debt facility, while advancing other clinical programs.

MoonLake Immunotherapeutics reports increased R&D expenses and net losses in Q2 2025, driven by advanced clinical trials, while securing significant debt financing to extend its cash runway into 2028.

MoonLake Immunotherapeutics reports a net loss of $40.6 million for Q1 2025, alongside updates on its clinical development programs and a new $500 million loan facility.

MoonLake Immunotherapeutics reported a net loss of $36.1 million for the third quarter of 2024, with significant increases in research and development expenses as the company advances its clinical programs.

MoonLake Immunotherapeutics reports increased R&D spending and a net loss for Q2 2024, while highlighting progress in clinical trials for Sonelokimab.

MoonLake Immunotherapeutics reported a net loss of $14.0 million for the first quarter of 2024, while highlighting progress in clinical trials and preparations for Phase 3 studies.